Next 10 |
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...
2024-06-19 09:27:56 ET Summary Nurix Therapeutics raised $209m in its IPO in July 2020, focusing on protein degradation in drug development, primarily in the blood cancer space. Protein degradation involves marking proteins for destruction by the proteasome using bifunctional smal...
2024-06-17 15:24:57 ET More on Nurix Therapeutics Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies Nurix Therapeutics files for mixed shelf securities offering Seeking Alpha’s Quant Rating on Nurix Therapeutics Historical...
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal t...
SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., P...
Oral presentation features structural disclosure and preclinical characterization of NX-2127, Nurix’s lead BTK degrader for the treatment of B-cell malignancies Poster presentation highlights specificity and potency of NX-5948 and superior cellular activity of both NX-2127 and ...
2023-04-14 13:00:16 ET Gainers: SAI.TECH Global Corporation ( SAI ) +166% . CXApp ( CXAI ) +80% . Oblong ( OBLG ) +88% . Allarity Therapeutics ( ALLR ) +57% . Marpai ( MRAI ) +33% . Eightco Holdings ( OCTO ) +34% . ...
2023-04-13 16:27:53 ET Nurix Therapeutics press release ( NASDAQ: NRIX ): Q1 GAAP EPS of -$0.75 beats by $0.13 . Revenue of $12.69M (+31.9% Y/Y) beats by $1.73M . Cash, cash equivalents and marketable securities was $325.6 million as of February 28, 2023 compar...
Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment Expanded therapeutic area potential of protein degradation pipeline with Gilead in rheumatoid arthritis and other inflammatory diseases A...
Nurix Therapeutics, Inc. (NASDAQ: NRIX) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 12.32% on the day to $10.12. Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and...
News, Short Squeeze, Breakout and More Instantly...
Nurix Therapeutics Inc. Company Name:
NRIX Stock Symbol:
NASDAQ Market:
Nurix Therapeutics Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal t...
SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., P...